Confidently keep an eye on CML
Oncology | Blood Cancer

Confidently keep an eye on CML

What is CML?

Chronic myeloid leukemia (CML) is a type of blood cancer that’s caused by a genomic alteration in myeloid blood-forming cells in the bone marrow. This leads to an overproduction of CML blood cells, and an eventual reduction in other healthy blood cells.

CML is also known as chronic myelogenous leukemia, chronic granulocytic leukemia or chronic myelocytic leukemia, and accounts for 15–20% of all adult leukemia cases.* It is classified by the WHO as a myeloproliferative neoplasm (MPN).**

What causes CML?

More than 95% of CML cases have an abnormal translocation of chromosomes 9 and 22 called the Philadelphia (Ph) chromosome, resulting in the BCR::ABL1 fusion gene. These CML cases are often referred to as Philadelphia chromosome positive (Ph+).*** 

The BCR::ABL1 gene instructs the abnormal blood cell —inside which the translocation occurred— to overproduce a protein called tyrosine kinase. The elevated tyrosine kinase activity leads to the development of CML cells.

For effective CML patient care and management, BCR::ABL1 Mbcr levels need to be measured routinely.

What causes CML?
How the BCR::ABL1 Cancer-Causing Gene (Oncogene) Is Formed

It's now easier than ever to monitor CML

Quantitation of BCR::ABL1 Mbcr transcripts by qPCR is essential to disease monitoring in CML patients.

With the International Scale (IS) standardization of BCR::ABL1 measurements, monitoring CML is now straightforward.

You can be sure you’re consistently interpreting clinical research data and using similar clinical decision values as other oncologist-hematologists.****

Real-world lab experiences

Find out how Mikrogen Lab improved BCR::ABL1 detection with our testing kits.

Thanks to the perfect experience with the ipsogen BCR-ABL1 Mbcr IS-MMR Kit, we plan to expand our test portfolio even more”
Volkan Baltacı, Pharmacogenetics Scientist and Founder of Mikrogen Genetic Diseases Diagnosis Center

How Mikrogen Lab improved CML patient care

With QIAGEN’s ipsogen BCR::ABL1 test solutions, Mikrogen Genetic Diseases Diagnosis Center could now offer speedy, specific and sensitive tests — significantly shortening their turnaround times.

The lab also began to enjoy fast and easy data analysis and reporting, in line with International Scale (IS) standardization.

Read the whole story
How Mikrogen Lab improved CML patient care
Volkan Baltacı, Founder of Mikrogen Genetic Diseases Diagnosis Center
IS-Standardized BCR::ABL1 Mbcr Testing
The ipsogen BCR-ABL1 Mbcr IS-MMR and ipsogen BCR-ABL1 Mbcr RGQ RT-PCR kits quantify BCR::ABL1 Mbcr transcripts directly to the WHO IS, and let you continuously monitor the molecular response.
Find out more

How Sue Branford is leading CML research

Professor Sue Branford is Head of the Leukemia Lab in the Department of Genetics and Molecular Pathology at SA Pathology. She is a National Health and Medical Research Council Research Fellow and leads the International Chronic Myeloid Leukemia Genomics Alliance. Learn about her journey and contributions to fighting CML.

Read her portrait
How Sue Branford is leading CML research

References

* Findakly D, Arslan W. Clinical Features and Outcomes of Patients With Chronic Myeloid Leukemia Presenting With Isolated Thrombocytosis: A Systematic Review and a Case From Our Institution. Cureus. 2020 Jun 23;12(6):e8788. doi: 10.7759/cureus.8788. PMID: 32596094; PMCID: PMC7314366.

** Daniel A. Arber, Attilio Orazi, Robert Hasserjian, Jürgen Thiele, Michael J. Borowitz, Michelle M. Le Beau, Clara D. Bloomfield, Mario Cazzola, James W. Vardiman; The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127 (20): 2391–2405. doi: https://doi.org/10.1182/blood-2016-03-643544

*** Sampaio MM, Santos MLC, Marques HS, Gonçalves VLS, Araújo GRL, Lopes LW, Apolonio JS, Silva CS, Santos LKS, Cuzzuol BR, Guimarães QES, Santos MN, de Brito BB, da Silva FAF, Oliveira MV, Souza CL, de Melo FF. Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review. World J Clin Oncol. 2021 Feb 24;12(2):69-94. doi: 10.5306/wjco.v12.i2.69. PMID: 33680875

**** Helen E. White, Paul Matejtschuk, Peter Rigsby, Jean Gabert, Feng Lin, Y. Lynn Wang, Susan Branford, Martin C. Müller, Nathalie Beaufils, Emmanuel Beillard, Dolors Colomer, Dana Dvorakova, Hans Ehrencrona, Hyun-Gyung Goh, Hakim El Housni, Dan Jones, Veli Kairisto, Suzanne Kamel-Reid, Dong-Wook Kim, Stephen Langabeer, Edmond S. K. Ma, Richard D. Press, Giuliana Romeo, Lihui Wang, Katerina Zoi, Timothy Hughes, Giuseppe Saglio, Andreas Hochhaus, John M. Goldman, Paul Metcalfe, Nicholas C. P. Cross; Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood 2010; 116 (22): e111–e117. doi: https://doi.org/10.1182/blood-2010-06-291641

In line with established HUGO Gene Nomenclature Committee (HGNC) recommendations for the fusion gene nomenclature (Bruford EA, et al. Leukemia. 2021, https://doi.org/10.1038/s41375-021-01436-6), we are implementing use of italics and double colon (::) for fusion genes designation (e.g. BCR::ABL1). However historical nomenclature (e.g. BCR-ABL1) may persist in our materials